Education
About Us
Working with TipRanks
Follow Us
LAVA Therapeutics (LVTX)
NASDAQ:LVTX
LVTX Stock Chart & Stats
$1.78
-$0.03(-2.78%)
At close: 4:00 PM EST
$1.78
-$0.03(-2.78%)
Day’s Range― - ―
52-Week Range$0.85 - $2.00
Previous CloseN/A
Volume31.56K
Average Volume (3M)430.90K
Market Cap
$42.75M
Enterprise Value-$20.66M
Total Cash (Recent Filing)$49.66M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.33
Next Earnings
Mar 19, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.27
Shares Outstanding26,305,296
10 Day Avg. Volume419,635
30 Day Avg. Volume430,902
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)0.92
Price to Sales (P/S)2.13
P/FCF Ratio-1.30
Enterprise Value/Market Cap-0.48
Enterprise Value/Revenue-4.14
Enterprise Value/Gross Profit1.06
Enterprise Value/Ebitda0.94
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
AcquisitionXOMA to acquire LAVA in cash-and-CVR deal, offering a definitive agreement for shareholders.
Clinical ProgressProgress continues with LAVA-1266, a Gammabody targeting CD123 for acute myeloid leukemia and myelodysplastic syndrome.
Financial PerformanceThe company reported license revenue of $5M and a net loss of $0.14 per share, better than the consensus estimate of revenue of $2.5M and a net loss of 0.30 per share.
Bears Say
Clinical ChallengesThe company's sole remaining wholly-owned clinical asset, LAVA-1266, lacks supportive clinical data.
Earnings ReportFor 1Q25, the company reported no revenue and a net loss of $0.13 per share.
Workforce ReductionIn February, the company announced a workforce reduction of approximately 30% and initiated a strategic review.
LAVA Therapeutics News
LVTX FAQ
What was LAVA Therapeutics’s price range in the past 12 months?
LAVA Therapeutics lowest stock price was $0.85 and its highest was $2.00 in the past 12 months.
What is LAVA Therapeutics’s market cap?
LAVA Therapeutics’s market cap is $42.75M.
When is LAVA Therapeutics’s upcoming earnings report date?
LAVA Therapeutics’s upcoming earnings report date is Mar 19, 2026 which is in 119 days.
How were LAVA Therapeutics’s earnings last quarter?
LAVA Therapeutics released its earnings results on Nov 12, 2025. The company reported -$0.267 earnings per share for the quarter, missing the consensus estimate of -$0.245 by -$0.022.
Is LAVA Therapeutics overvalued?
According to Wall Street analysts LAVA Therapeutics’s price is currently Overvalued.
Does LAVA Therapeutics pay dividends?
LAVA Therapeutics does not currently pay dividends.
What is LAVA Therapeutics’s EPS estimate?
LAVA Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does LAVA Therapeutics have?
LAVA Therapeutics has 26,305,296 shares outstanding.
What happened to LAVA Therapeutics’s price movement after its last earnings report?
LAVA Therapeutics reported an EPS of -$0.267 in its last earnings report, missing expectations of -$0.245. Following the earnings report the stock price went down -0.621%.
Which hedge fund is a major shareholder of LAVA Therapeutics?
Currently, no hedge funds are holding shares in LVTX
LAVA Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
― (―)
― (―)
Hedge Fund Trend
Decreased
By 521.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $11.7M over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
-10.30%
12-Months-Change
Fundamentals
Return on Equity
-101.50%
Trailing 12-Months
Asset Growth
-34.39%
Trailing 12-Months
Company Description
LAVA Therapeutics
LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company, through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-051, which is in Phase 1/2a clinical trial for blood cancers, including chronic lymphocytic leukemia, multiple myeloma, and acute myeloid leukemia; and LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is also developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 and LAVA-1278, which are preclinical candidates for the treatment of various hematologic malignancies. LAVA Therapeutics N.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use. The company was incorporated in 2016 and is headquartered in Utrecht, the Netherlands.
Technical Analysis
Ownership Overview
19.08% Insiders
2.04% Mutual Funds
<0.01% Other Institutional Investors
78.88% Public Companies and
Individual Investors